Doctors may consider anti-obesity medicines sooner than many patients expect, but side effects, long-term use and high costs remain significant barriers.
Obesity remains a major long-term health problem, and the World Health Organization says the global burden has continued to rise sharply. Its latest figures show that in 2024, 2.6 billion adults were overweight and 940 million were living with obesity, underscoring how common the condition has become across every region. The agency defines overweight and obesity as abnormal or excessive fat accumulation that can harm health, and says higher-than-optimal body mass index contributed to an estimated 5 million noncommunicable disease deaths in 2019.
Against that backdrop, Dr. Jillian Foglesong Stabile, writing for HealthDay and medically reviewed by Drugs.com, argues that weight-loss medication deserves consideration much earlier than many patients expect. She says adults may qualify if their body mass index is 30 or higher, or 27 or higher when weight-related conditions such as type 2 diabetes, high blood pressure or sleep apnea are present. In practice, doctors often begin with diet and exercise, but if those changes fail to produce at least a 5% reduction in body weight, medication may become a reasonable next step.
The article also notes that there is no fixed waiting period before treatment can begin. Some medical groups support using medication alongside lifestyle changes as part of first-line care when the clinical need is clear, rather than delaying treatment until repeated attempts have failed. That approach reflects a broader shift in obesity care: for many patients, medication is no longer viewed as a last resort but as one tool within a long-term treatment plan.
Several medicines are now available, including tirzepatide and semaglutide, which have drawn attention for producing substantial weight loss in many patients when combined with healthy eating and regular activity. Other options, such as phentermine-topiramate, naltrexone-bupropion and orlistat, may also help, though the typical weight loss is often more modest. The article says these drugs work in different ways, including reducing appetite, helping people feel full sooner or limiting fat absorption. Beyond weight loss, some of these medicines can improve blood sugar control in people with diabetes and may also help with sleep apnea, fatty liver disease, chronic kidney disease and cardiovascular risk.
Even so, the piece stresses that these medicines are not a quick fix. Side effects, individual response and interactions with other drugs all need to be discussed with a clinician, and periodic follow-up is important to make sure treatment remains safe and effective. The article also points out a practical barrier: many insurers still do not cover anti-obesity drugs, leaving patients to face monthly costs that can run from hundreds to thousands of dollars. For people who do respond, treatment is usually long term, since stopping medication often leads to weight regain.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
